The anti-ovarian cancer activity by WYE-132, a mTORC1/2 dual inhibitor

Tumor Biology

Volumn 37, Issue 1, 2016, Pages 1327-1336

  Zhang, Dan ^a,b   Xia, Hexia ^b   Zhang, Wei ^b   Fang, Bo ^b  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Apoptosis; Epithelial ovarian cancer; mTORC1 2; Taxol sensitization and SphK1; WYE 132

Indexed keywords

1 [4 [1 (1,4 DIOXASPIRO[4.5]DEC 8 YL) 4 (8 OXA 3 AZABICYCLO[3.2.1]OCT 3 YL) 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]PHENYL] 3 METHYLUREA; CERAMIDE; CYCLIN D1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PACLITAXEL; SPHINGOSINE KINASE 1; CARBANILAMIDE DERIVATIVE; CASP3 PROTEIN, HUMAN; CASPASE 3; CCND1 PROTEIN, HUMAN; ENZYME INHIBITOR; HIF1A PROTEIN, HUMAN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PHOSPHOTRANSFERASE; PYRAZOLE DERIVATIVE; SPHINGOSINE KINASE; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ADULT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; MIDDLE AGED; OVARY CANCER; PRIORITY JOURNAL; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CHEMISTRY; GENETICS; METABOLISM; MOUSE; NUDE MOUSE; OVARY TUMOR; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; ENZYME INHIBITORS; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, NUDE; MIDDLE AGED; MULTIPROTEIN COMPLEXES; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; PACLITAXEL; PHENYLUREA COMPOUNDS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PYRAZOLES; TOR SERINE-THREONINE KINASES;

EID: 84939613511     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3922-0     Document Type: Article

References (41)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
2. Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013;13:273–82.
3. Vaughan S, Coward JI, Bast Jr RC, Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11:719–25.
4. Li XH, Chen XJ, Ou WB, Zhang Q, Lv ZR, Zhan Y, et al. Knockdown of creatine kinase B inhibits ovarian cancer progression by decreasing glycolysis. Int J Biochem Cell Biol. 2013;45:979–86.
5. Meng Q, Xia C, Fang J, Rojanasakul Y, Jiang BH. Role of Pi3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70s6K1 pathway. Cell Signal. 2006;18:2262–71.
6. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489–501.
7. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005;24:7455–64.
8. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 2005;9:59–71.
9. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12:9–22.
10. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006;6:729–34.
11. Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 2004;23:5853–7.
12. Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene. 2006;25:6436–46.
13. Griner SE, Joshi JP, Nahta R. Growth differentiation factor 15 stimulates rapamycin-sensitive ovarian cancer cell growth and invasion. Biochem Pharmacol. 2013;85:46–58.
14. Wu R, Hu TC, Rehemtulla A, Fearon ER, Cho KR. Preclinical testing of pi3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clin Cancer Res. 2011;17:7359–72.
15. Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley HH, et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res. 2007;13:4261–70.
16. Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2009;27:193–8.
17. Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, Reddy SA, et al. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer. 2010;10:368.
18. Garrido-Laguna I, Tan AC, Uson M, Angenendt M, Ma WW, Villaroel MC, et al. Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br J Cancer. 2010;103:649–55.
19. Vilar E, Perez-Garcia J, Tabernero J. Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ther. 2011;10:395–403.
20. Sun SY. mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Lett. 2013;340:1–8.
21. Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, Kim JE, et al. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res. 2010;70:621–31.
22. Yu K, Toral-Barza L. Biochemical and pharmacological inhibition of mTOR by rapamycin and an ATP-competitive mTOR inhibitor. Methods Mol Biol. 2012;821:15–28.
23. Sun H, Yu T, Li J. Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: more than just AKT inhibition. Cancer Lett. 2011;310:118–28.
24. Yao C, Wu S, Li D, Ding H, Wang Z, Yang Y, et al. Co-administration phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase-1 (Sphk1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth both in vivo and in vitro. Mol Oncol. 2012;6:392–404.
25. Ji F, Mao L, Liu Y, Cao X, Xie Y, Wang S, et al. K6PC-5, a novel sphingosine kinase 1 (Sphk1) activator, alleviates dexamethasone-induced damages to osteoblasts through activating Sphk1-Akt signaling. Biochem Biophys Res Commun. 2015;458:568–75.
26. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE, et al. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res. 2005;11:7490–8.
27. Averous J, Fonseca BD, Proud CG. Regulation of Cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1. Oncogene. 2008;27:1106–13.
28. Toschi A, Lee E, Gadir N, Ohh M, Foster DA. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J Biol Chem. 2008;283:34495–9.
29. Tazuke SI, Mazure NM, Sugawara J, Carland G, Faessen GH, Suen LF, et al. Hypoxia stimulates insulin-like growth factor binding protein 1 (IGFBP-1) gene expression in HEPG2 cells: a possible model for IGFBP-1 expression in fetal hypoxia. Proc Natl Acad Sci U S A. 1998;95:10188–93.
30. Shida D, Takabe K, Kapitonov D, Milstien S, Spiegel S. Targeting Sphk1 as a new strategy against cancer. Curr Drug Targets. 2008;9:662–73.
31. Yang YL, Ji C, Cheng L, He L, Lu CC, Wang R, et al. Sphingosine kinase-1 inhibition sensitizes curcumin-induced growth inhibition and apoptosis in ovarian cancer cells. Cancer Sci. 2012;103:1538–45.
32. Zhang H, Wang Q, Zhao Q, Di W. Mir-124 inhibits the migration and invasion of ovarian cancer cells by targeting Sphk1. J Ovarian Res. 2013;6:84.
33. Chiba Y, Takeuchi H, Sakai H, Misawa M. Ski-ii, an inhibitor of sphingosine kinase, ameliorates antigen-induced bronchial smooth muscle hyperresponsiveness, but not airway inflammation, in mice. J Pharmacol Sci. 2010;114:304–10.
34. Masamha CP, Benbrook DM. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of Cyclin E2 in ovarian cancer cells. Cancer Res. 2009;69:6565–72.
35. Worsley SD, Ponder BA, Davies BR. Overexpression of Cyclin D1 in epithelial ovarian cancers. Gynecol Oncol. 1997;64:189–95.
36. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 2008;15:678–85.
37. Huo HZ, Zhou ZY, Wang B, Qin J, Liu WY, Gu Y. Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. Biochem Biophys Res Commun. 2014;443:406–12.
38. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence Jr JC, Abraham RT. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and ly294002. EMBO J. 1996;15:5256–67.
39. Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2014;15:396–405.
40. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase iii trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage iii ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2003;21:3194–200.
41. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099–106.